Program
bofanglutide
Also written as “GZR18”, “GZR18 injection” and “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive, led by 2 companies.
Drug pageBofanglutide: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticalsits history only | 237 open or running | phase 3since Dec 5, 2024 | Feb 25, 2022 | Jun 30, 2027phase 3 · NCT07150975 |
| Carnot Laboratories | 22 open or running | phase 3since May 24, 2026 | May 24, 2026 | Oct 2027phase 3 · NCT07628985 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Carnot Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 29, 2024Named bofanglutideINNProposed as its International Nonproprietary Name in WHO's List 130
- May 24, 2026First studies: 2 phase 3 studiesFirst studyNCT07628985, NCT07622810
Ahead
- Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07628985
- Dec 2027Primary completion: phase 3 study in ObesityNCT07622810
TargetBeta
“Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 2 Carnot Laboratories leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07628985Diabetes Mellitus, Type 2 · Mexico | 3 | Not yet recruiting | Oct 2027 | 374 |
| NCT07622810Obesity · Mexico | 3 | Not yet recruiting | Dec 2027 | 352 |
How it is read
Names in the registry
- “GZR18”, 13 entries
- “GZR18 injection”, 8 entries
- “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”, 1 entry
- “GZR18 injection A”, 1 entry
- “GZR18 injection B”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 10 studies
- Sleep Apnea, Obstructive, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.